In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Vascular Biogenics (VBLT), with a price target of $3. The company’s shares closed yesterday at $1.56.
Ramakanth commented:
“We maintain our Buy rating of VBLT and our 12-month price target of $3.00 per share. We derive our price target based on the average of two valuation methods: (1) price-sales multiple analysis applying a 6x multiple to our 2026 sales estimate discounted at 18%; and 2) price-earnings multiple analysis applying a 19x multiple to our 2026 estimated earnings discounted at 18%. (1) clinical; (2) regulatory; (3) commercial; (4) partnership; (5) financial; and (6) intellectual property.”
According to TipRanks.com, Ramakanth is ranked 0 out of 5 stars with an average return of -4.4% and a 33.8% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Gritstone Oncology Inc.
Currently, the analyst consensus on Vascular Biogenics is a Moderate Buy with an average price target of $3.
See today’s analyst top recommended stocks >>
Based on Vascular Biogenics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $5.35 million. In comparison, last year the company had a net profit of $6.31 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vascular Biogenics Ltd. is in the clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of first-in-class treatments for cancer. It offers different programs for cancer and inflammatory disease patients such as vascular targeting system and Lecinoxoids.
